LifeMD 2025 Q3 Earnings Narrowed Net Loss by 25.7% Amidst Revenue Growth

LifeMD (LFMD) reported mixed results for Q3 2025, with revenue growth outpacing improved profitability. The company missed revenue estimates and revised 2025 guidance downward following the WorkSimpli divestiture. Despite these challenges, LifeMD narrowed its net loss by 25.7% year-over-year and reported a 13% revenue increase.

Revenue

LifeMD’s total revenue rose 13.0% to $60.17 million in Q3 2025, driven by robust telehealth services. Telehealth revenue, net, rose to $47.28 million, while WorkSimpli revenue, net, contributed $12.89 million. The combined segments totaled $60.17 million in total revenues, net, reflecting the company’s continued reliance on telehealth for growth.

Earnings/Net Income

The company narrowed its net loss to $-3.56 million in Q3 2025, a 25.7% reduction from $-4.79 million in 2024 Q3. Earnings per share (EPS) improved from a loss of $0.13 to $0.10, marking a 23.1% improvement. The narrowing of losses and 9-year high in Q3 net income indicate improved financial performance.

Post-Earnings Price Action Review

Following the earnings release, LifeMD’s stock price declined sharply, dropping 3.47% in the latest trading day, 7.80% for the week, and 26.44% month-to-date. The results fell short of analyst expectations, with revenue missing estimates by $1.93 million and EPS undershooting by $0.06. Cantor Fitzgerald reiterated its Overweight rating and $15.00 price target, while BTIG lowered its target to $10.00 amid competitive pressures in the weight management segment. Despite these challenges, telehealth subscribers grew 14% year-over-year to 310,800, and the company reported a 30% rise in adjusted EBITDA.

CEO Commentary

CEO Justin Schreiber highlighted progress in Q3 2025, including RexMD’s 10,000 net subscriber additions and strategic investments in women’s and behavioral health. He emphasized collaborations with Novo Nordisk and Eli Lilly as competitive advantages and expressed confidence in the company’s integrated model and regulatory readiness to drive 2026 growth.

Guidance

LifeMD provided Q3 2025 revenue of $60.2 million and adjusted EBITDA of $5.1 million. Full-year 2025 revenue guidance was revised to $192M–$193M, down from $250M–$255M, with adjusted EBITDA of $13.5M–$14.5M. Q4 revenue is expected to range $45M–$46M, with adjusted EBITDA of $3M–$4M.

Additional News

1. Cantor Fitzgerald Rating: Cantor Fitzgerald reiterated an Overweight rating and $15.00 price target, citing growth levers in weight management, mental health, and hormone therapy.

2. BTIG Price Target Cut: BTIG reduced its target to $10.00 from $18.00, maintaining a Buy rating, due to competitive pressures in the weight management segment.

3. Stock Price Drop: Shares plunged 16% in after-hours trading after missing revenue and EPS estimates, with cash reserves at $23.8 million as of Q3 end.

Polished Article

LifeMD’s Q3 2025 earnings reflect a mixed performance, balancing revenue growth with persistent profitability challenges. While telehealth revenue and adjusted EBITDA improved, the company faces near-term headwinds from low-cost GLP-1 competitors. Strategic initiatives in women’s health and regulatory milestones position it for long-term growth, but near-term execution will be critical.